Myomo (NYSEAMERICAN:MYO) Issues Earnings Results

Myomo (NYSEAMERICAN:MYO) posted its quarterly earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01, Zacks reports. The company had revenue of $12.33 million during the quarter, compared to the consensus estimate of $11.51 million. Myomo had a negative net margin of 33.53% and a negative return on equity of 138.85%.

Here are the key takeaways from Myomo’s conference call:

• Revenue reached a record $12.3 million, up 22% year over year, while gross margin increased to 71.3% from 63.8% and adjusted EBITDA reached approximately break-even.
• Recurring patient sources rose to 54% of revenue from 33% a year ago, and MyoConnect had referrals from more than 500 facilities. The company also reported a record 258 orders and payer agreements or pending agreements covering an additional 35 million lives.
• Myomo narrowed its 2026 revenue outlook to $46 million–$47 million, from the prior $45 million–$47 million range, and expects second-half cash burn below $2 million. Management expects a modest sequential gross-margin increase in Q4, though operating expenses are expected to rise modestly.
• Pipeline additions fell to 600, with management citing summer-season effects, temporary MyoConnect staffing constraints, and inefficient direct-to-patient lead generation. October direct-billing pipeline additions improved about 30% from the Q3 monthly average, but Q4 pipeline activity is typically seasonally lower.
• Net loss was $4.2 million versus $3.7 million a year earlier, despite a narrower operating loss; results included an approximately $1.8 million non-cash derivative-liability valuation charge and interest expense tied to the term loan.

Myomo Stock Up 15.7%

Shares of MYO stock opened at $1.40 on Tuesday. The stock has a fifty day moving average price of $1.38 and a 200 day moving average price of $1.09. The company has a quick ratio of 2.01, a current ratio of 2.31 and a debt-to-equity ratio of 1.98. Myomo has a 1 year low of $0.60 and a 1 year high of $1.89.

Key Myomo News

Here are the key news stories impacting Myomo this week:

• Positive Sentiment: Third-quarter revenue rose 22.2% year over year to $12.3 million, beating analyst estimates. Gross profit increased 36.4% to $8.8 million, and Myomo reported breakeven adjusted EBITDA. Myomo Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Myomo set 2026 revenue guidance at $46 million to $47 million, above the roughly $45.5 million analyst consensus. Management expects modest sequential gross-margin improvement in the fourth quarter. Myomo narrows 2026 revenue guidance
• Negative Sentiment: The quarterly loss was $0.10 per share, wider than the $0.08 consensus estimate. Myomo also recorded a $4.2 million net loss and $1.3 million in operating cash outflow, highlighting that it remains unprofitable and is using cash. Myomo Q3 2026 earnings summary

Insider Buying and Selling at Myomo

In other news, insider Harry Kovelman sold 17,250 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $1.73, for a total value of $29,842.50. Following the sale, the insider directly owned 105,983 shares in the company, valued at $183,350.59. This represents a 14.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 47,738 shares of company stock valued at $70,662 in the last three months. Company insiders own 12.14% of the company’s stock.

Myomo Company Profile

Myomo, Inc is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand.

The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.